Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System. January 7, 2025 Prostate Cancer Patient With Lymph-node Metastasis Treated Only With ...

The Value and Limitations of Biopsies for Small Renal Masses - Phillip Pierorazio ...

Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

Advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains one of the most challenging malignancies to treat. While androgen-deprivation therapies and next ...

It is estimated that a total of 0.9 million patients with prostate cancer would potentially require radiotherapy in the year 2024 across all income groups and would have considerable variation in ...

Diane Newman and Don Darais delve into the specifics of catheter design and the importance of 'eyelets.' They explain that these holes, located on the sides of the catheter and not the tip, allow ...

Partial Component Exchange of a Non-Infected Inflatable Penile Prosthesis Is Associated with a Higher Complication Rate - Beyond the Abstract ...

PSMA-PET/CT has emerged as a superior diagnostic tool for prostate cancer, demonstrating enhanced accuracy over conventional imaging methods. Although sensitive for detecting local and metastatic ...

Ultrahypofractionation presents challenges for a subset of high-risk prostate cancer patients due to the large planning target volume (PTV) margin required for the seminal vesicles. Online adaptive ...

In NCCN favorable intermediate-risk (FIR) prostate cancer (PCa) patients treated with radical prostatectomy (RP), we tested the effect of upstaging and upgrading on cancer-specific mortality (CSM).

The introduction of vascular endothelial growth factor receptor-tyrosine kinases (VEGFR-TKIs) and immune checkpoint inhibitors (IOs) have drastically altered the treatment landscape for kidney cancer, ...